George K. Abruzzo

Statistics

Publications

Citations

4.2K

H-Index

Active since

1981

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

MSD (Spain)

Scynexis (United States)

Merck Canada Inc. (Canada)

George K. Abruzzo is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in antifungal agents, new antifungal agents, and mycology.

Publications per year

1981–2020

Publications

Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical <i>Candida</i> sp. Isolates

S. Park, Rosemarie Kelly, Jennifer Nielsen Kahn et al. · Antimicrobial Agents and Chemotherapy · 2005 · 432 citations

Life Sciences, Microbiology, Molecular Biology +17

Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors

Cameron Douglas, Joseph A. D'Ippolito, G.-J. Shei et al. · Antimicrobial Agents and Chemotherapy · 1997 · 339 citations · Full text

Life Sciences, Microbiology, Molecular Biology +17

Discovery of Novel Antifungal (1,3)-β- <scp>d</scp> -Glucan Synthase Inhibitors

Janet C. Onishi, M. Meinz, John R. Thompson et al. · Antimicrobial Agents and Chemotherapy · 2000 · 319 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

K Bartizal, Christopher Gill, George K. Abruzzo et al. · Antimicrobial Agents and Chemotherapy · 1997 · 312 citations · Full text

Life Sciences, Microbiology, Pharmacology +14

Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

George K. Abruzzo, Amy Flattery, Christopher Gill et al. · Antimicrobial Agents and Chemotherapy · 1997 · 245 citations · Full text

Medicine, Microbiology, Pharmacology +17

1–5 of 50